Breast cancer remains the most prevalent cancer among women in the United States. Substance P, a peptide derived from the TAC1 gene, mediates oncogenic properties in breast and other cancers. TAC1 expression facilitates the entry of breast cancer cells into bone marrow. The transcriptional repressor element 1-silencing transcription factor (REST) has been implicated in both oncogenic and tumor-suppressor functions. REST binds to the 5 untranslated region of the TAC1 promoter and suppresses its expression. This study investigated a role for REST in TAC1 induction in breast cancer. Western blots and real-time PCR indicated that REST expression in breast cancer cells was inversely proportional to the cells' aggressiveness, for both cell lines and primary breast cancer cells. REST knockdown in low-metastatic T47D cells and nontumorigenic MCF12A cells resulted in increases in TAC1 induction, proliferation, and migration. These parameters were negatively affected by ectopic expression of REST in highly aggressive MDA-MB-231 cells. Together, these findings show a central role for REST in the oncogenic function of TAC1 and suggest a tumor-suppressor role for REST in breast cancer.
D
espite advances in diagnostic technologies and treatments, breast cancer (BC) continues to be among the leading causes of cancer-related deaths among women (1) . The TAC1 gene has been implicated in the development of breast and other cancers (2) (3) (4) . TAC1 (preprotachykinin-A) is a single-copy gene with 7 exons (5). Through alternative splicing and posttranslational modification, TAC1 produces peptides belonging to the tachykinin family (5-7). Substance P (SP) is the predominant peptide produced from TAC1 (8, 9) .
BC cells (BCCs) produce high levels of SP (6) . SP binds with varying affinities to 3 G protein-coupled, 7-transmembrane receptors: neurokinin (NK)1, NK2, and NK3 (6, 10) . NK1 and NK2 have been reported on BCCs. SP mediates BCC proliferation, imparts radiation resistance, protects from apoptosis, induces growth-and angiogenic-promoting factors, and facilitates BC metastasis to bone marrow (2, 4, 11, 12) . The truncated NK1 has also been linked to oncogenesis, partly through the induction of TAC1 (2) .
Stromal-derived factor-1␣, which is implicated in BC biology, regulates TAC1 expression (4, 13) . Other cytokines also induce TAC1 expression in BCCs via autocrine stimulation (2, 14) . RE-1 silencer of transcription (REST) represses TAC1 expression in mesenchymal stem cells (15) . The link between REST and TAC1 could be relevant to disorders such as tumorigenesis and hippocampal seizure (16) .
REST, also known as neural restrictive silencing factor, is a zinc finger transcriptional repressor of neuronal genes in nonneuronal and immature neuronal cells (17) . REST facilitates chromatin remodeling and inhibits gene expression by assembling a repressor complex (18) , Sin3A/histone deacetylase, and co-REST at the N and C termini, respectively (18) . REST has been implicated in both oncogenic and tumor-suppressor roles (19, 20) . An oncogenic property has been indicated by its increase in combination with myc in medulloblastoma (21) . A tumor-suppressor role has been reported for colon and small-cell lung cancers (SCLC) (22) (23) (24) . In breast, colon, lung, and prostate cells, REST suppresses the expressions of neuroendocrine genes and activation of the phosphatidylinositol 3-kinase [PI (3)K] pathway, suggesting negative regulation on cell transformation (19, 23) . REST mutation results in a loss of its repressor function, with stimulation of the PI (3)K pathway and cell transformation (19, 22, 23) . REST and NFB synergistically repress TAC1 expression in mesenchymal stem cells and bone marrow stroma (15) . Here we report on decreased REST expression in TAC1 induction in BCCs. The results are verified with primary BC tissues from different stages of the disease.
Results

REST Expression in BCCs.
To explore the function of REST in BC, we first determined REST expression in the cell lines MDA-MB-231 and T47D and then compared with the cell line MCF12A. The lowest level in MDA-MB-231 was assigned a value of 1 for relative expression of MCF12A and T47D. There was a significant (P Ͻ 0.05) increase for T47D but lower than for MCF12A (P Ͻ 0.05) (Fig. 1A) . Western blots showed consistency for protein ( Fig. 1 B and C) . In summary, REST expression was reduced with tumorigenicity: MCF12A Ͼ T47D Ͼ MDA-MB-231.
TAC1 Expression in REST Knockdown
BCCs. The 5Ј untranslated region of TAC1 has a functional REST binding site (15) . Because BCCs show high expression of TAC1 (3, 4), we asked whether its increase can be explained by decrease in REST expression. We stably knocked down REST (wild type) in MDA-MB-231, T47D, and MCF12A and then studied TAC1 reporter activity by transfection with pGL3-TAC1-1.2 (25) . Controls included nontransfectants and mutant siRNA (mt) transfectants. RT-PCR and Western blot verified REST knockdown ( Fig. 2 A and B) . REST knockdown resulted in significantly (P Ͻ 0.05) greater luciferase activities as compared with controls (Fig. 2C) . Realtime PCR for mRNA and ELISA for SP showed correlations between reporter gene activities and endogenous TAC1 expression ( Fig. 2D and Table 1 ).
Effects of REST on the Growth of BCCs. REST knockdown causes an increase in TAC1 expression (Fig. 2) . We determined whether REST knockdown could lead to increases in cell proliferation
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Freely available online through the PNAS open access option. 1 To whom correspondence should be addressed. E-mail: rameshwa@umdnj.edu. and migration. This would be consistent with the transforming ability of TAC1 (3) . REST knockdown did not show a significant (P Ͼ 0.05) change in the proliferation of MDA-MB-231 but showed significant (P Ͻ 0.05) increases for T47D and MCF12A (Fig. 3 A-C) . REST knockdown showed increases in activated AKT [phospho (P)-AKT] in T47D and MCF12A, which correlated with increases in proliferation (Fig. 3D ). In the case of MDA-MB-231 there were similar band intensities for P-AKT, regardless of REST expression (Fig. 3D) . Similarly, there was no significant (P Ͼ 0.05) change in migration for MDA-MB-231 ( Fig. 4A ) but significant (P Ͻ 0.05) increases for T47D and MCF12A (Fig. 4A ).
To address a role for TAC1, we knocked down REST in MCF12A, which causes an increase in SP (Table 1) , and then studied the cells' proliferation and migration in the presence or absence of specific NK1 and NK2 receptor antagonists (10 nM each). The results show significantly (P Ͻ 0.05) reduced proliferation in the presence of these antagonists with REST knockdown (wild-type siRNA) as compared with the other experimental points (Fig. 4B) . Similarly, these antagonists showed significant reduction in cell migration (Fig. 4C ). In summary, TAC1 has a role in the responses of MCF12A after REST knockdown. . We asked whether these properties, as well as TAC1 expression, could be reversed by ectopic REST. Because MCF12A and T47D express significant levels of REST as compared with MDA-MB-231 ( Fig. 1 ), they were not included in the studies. Western blot and real-time PCR verified ectopic REST expression ( Fig. 5 A and B) . As compared with nontransfectants and vector transfectants, ectopic REST showed a significant (P Ͻ 0.05) decrease in endogenous TAC1 expression for mRNA ( Fig.  5C ) and protein for SP (Table 2 ). In addition, there was significant (P Ͻ 0.05) decreases in proliferation and migration for ectopic REST expression as compared with vector transfectant and nontransfectant ( Fig. 6 A and B) . Western blots with Day-5 cell extracts showed undetectable caspase 3 (not shown) but detectable Bcl-2, indicating that reduced cell proliferation was not due to cell death (Fig. 6A, Inset) . In addition, daily trypan blue exclusion showed no evidence of cell death. In summary, ectopic REST expression in MDA-MB-231 resulted in decreased TAC1 induction, proliferation, and migration.
REST Expression in Primary Breast Tumors.
Because the studies presented in Figs. 1-6 support tumor-suppressor functions of REST, we studied its expression in primary BCCs from patients with varying stages of BC (Table 3) . Real-time PCR and Western blots for REST mRNA and protein, respectively, show decreased REST expression as the tumor stage increases ( Fig. 7 A and B) . Despite the limited cohort of patients, the data correlated with the studies performed with cell lines. This indicates that reduced REST expression correlates with the aggressiveness of the disease. Discussion TAC1 and its major peptide, SP, have been reported to exert an oncogenic role (2, 3, 11) . Cytokines have been implicated in the induction of TAC1 in BCCs. However, the mechanisms of overexpressed TAC1 in BCCs remain unclear. We report a role for the REST gene in the induction of TAC1 in BC. REST has been shown to exert both oncogenic and tumor-suppressor functions (19, 26) . Our results demonstrate a tumor-suppressor function of REST and that its loss or reduced expression result in TAC1 induction. In addition, REST expression is indirectly proportional to the tumorigenicity of BC (Figs. 4 and 7) .
The findings are significant to translational medicine because REST could be a prognostic and diagnostic biomarker for carcinogenesis. However, the clinical utility of REST requires in-depth studies to understand the mechanisms by which REST mediates tumor suppression. The 5Ј flanking region of TAC1 has a functional binding site for REST (15) . We showed decreased REST expression in advanced stages of BC. In contrast, TAC1 expression is increased in advanced BC (3, 4) . This study verified a cause-effect relationship between REST and TAC1 expressions using both knockdown and expression studies (Figs. 2 and  5 ). Although REST knockdown increased TAC1 expression in all BCCs, its loss did not change the proliferation and migration in the highly aggressive MDA-MB-231 (Figs. 3 and 4) . This is expected because endogenous REST expression was significantly lower in MDA-MB-231 as compared with T47D (Fig. 1) . Thus, TAC1 expression might have been at its optimum. Hence, a threshold level for REST could be required for oncogenic transformation, as well as aggressiveness.
Although knockdown of low levels of endogenous REST could not reverse proliferation and migration in MDA-MB-231, ectopic expression resulted in decreased TAC1 expression, pro- BCCs were stably knocked down for REST. Controls were untransfected (wt) or transfected with mutant (mt) REST. At 80% confluence, culture media were replaced with media containing 2% FCS. After 24 h, media were quantitated for SP and the results presented as mean SP Ϯ SD (pg/mL; n ϭ 5). * , P Ͻ 0.05 vs. REST siRNA (mt) and nontransfectants. Table 2 ), suggesting a link between the aggressiveness of MDA-MB-231 and REST expression. These findings are consistent with the observations in primary BCCs (Fig. 7) . Interestingly, the expression of REST was indirectly proportional to the stages of BC. However, it should be noted that because stage is not always synonymous with aggressiveness in BC, further studies are needed to validate these highly suggestive preliminary findings. On the basis of the combined results of cell lines and primary cells, it seems that an initial decrease in REST expression might initiate cell transformation via increased TAC1 expression, and continued decrease could cause aggression. Low expression of REST in MDA-MB-231 might activate pathways, independent of those signaled by TAC1 peptide, as identified by continued activation of AKT, despite REST knockdown (Fig. 3D) . Decrease in REST expression has been shown to activate PI (3)K and predispose the cells to transformation (22, 23) .
Cytokine induction has been implicated in the expression of TAC1 in BCCs (2, 3, 14) . Thus, it would be interesting to determine whether cytokines are upstream of the REST-TAC1 axis. IL-1␣ caused rapid decrease in REST expression (15) . It is predicted that enhanced cytokine induction may activate NF-B, which in turn could lead to the generation of truncated NK1 in BCCs (2) . On the basis of these segmented reports, it is possible that there is a complex network involving TAC1, REST, and cytokines in BC biology. The unraveling of such networks could identify potential avenues for therapeutic intervention. In addition to cytokines, neurotrophic factors could also be involved, given that downregulated REST expression in nonneuronal cells causes dysfunction in neurotrophins such as BDNF and their receptors, such as TrkC, which can promote cellular transformation and malignancy in nonneuronal cells (27) .
REST has also been reported to exert tumor suppression in SCLC (24) . Expression of the neuroendocrine peptide arginine vasopressin (AVP) distinguishes SCLC from normal lung and other neoplastic lung cell types, and this anomaly is believed to be prevented by the normal repressor activity of REST at the REST was expressed in MDA-MB-231. Controls were untransfected or transfected with vector alone. Culture media were quantitated for SP as for Table  1 and the results presented as mean Ϯ SD (n ϭ 5). *P Ͻ 0.05 vs. untransfected and vector transfectants.
AVP promoter region (24) . Interestingly, SCLCs express high levels of a splice variant of REST, which antagonizes RESTmediated repression of AVP, thereby promoting tumorigenesis of neuronal phenotype (19, 26, 28) . Similarly, a truncated form of REST has been shown to downregulate the expression of REST in colon cancer (23) . Because REST recruits cofactors through its C and N termini (26) , it is possible that the truncated forms might hinder tumor suppression owing to their inability to recruit cofactors. In this study, we did not observe any of the REST isoforms.
REST has been known to modulate the expressions of several genes. This study shows a tumor-suppressor role in BC, with a link to TAC1 expression (Fig. 4) , thereby initiating studies to characterize the molecular mechanisms of REST dysregulation during different stages of BC, as well as triple-negative BCCs, as identified by MDA-MB-231. Investigation of such pathways will lead to further knowledge of developmental and pathologic processes in neuroendocrine systems and cancer cell biology. Eventually, such progress will serve to improve diagnosis and treatment of BC.
Materials and Methods
Reagents. Rabbit anti-REST, anti-AKT, and anti-P-AKT were purchased from Upstate Cell Signaling, HRP-goat antirabbit IgG from BD PharMingen, mouse anti-␤-actin and HRP-goat antimouse IgG from Sigma. CP-96,345 and SR 48968 are nonpeptide antagonists for NK1 and NK2 receptors, respectively. CP-96,345 was obtained from Pfizer and SR 48968 from Sanofi Recherche.
Cell Lines and Primary Breast Cells. The cell lines MCF12A, T47D, and MDA-MB-231 were purchased from the American Type Culture Collection and propagated according to their instructions. MCF12A is a nontumorigenic breast epithelial cell line. T47D, a low-metastatic cell line, was derived from pleural effusion of ductal carcinoma. MDA-MB-231, a highly metastatic and invasive cell line, was derived from pleural effusion of an adenocarcinoma.
Breast tissues from surgical specimens were acquired from Brookdale University Hospital (Brooklyn, NY). At the time of surgery, patients were not subjected to any treatment. The studies were approved by the institutional review board of the University of Medicine and Dentistry of New Jersey and Brookdale University Hospital. Tissues from 4 patients were provided by the Cooperative Human Tissue Network. The demographics of patients are shown in Table 3 .
Vectors and Stable Transfectants. Construction of the siRNA vectors pPMSKH1-RESTwt and pPMSKH1-RESTmt has been previously described (15) . Briefly, for the REST siRNA wild-type sequence (pPMSKH1-RESTwt) spans ϩ1550/ϩ1568: 5Ј gtg taa tct aca gta tca c 3Ј (GenBank no. NM005612). Mutant siRNA REST expression in primary breast biopsies. Real-time PCR and Western blots for REST mRNA (A) and protein (B), respectively, in breast tissues at varying stages of BC. mRNA levels for nonmalignant cells were assigned values of 1 and the results presented as mean Ϯ SD (n ϭ 5). Western blots were normalized for ␤-actin, and the results are shown as normalized band densities. *, P Ͻ 0.05 vs. nonmalignant tissues. 46-83 ϩ/ϩ/Ϫ III All samples were obtained from female subjects whose staging followed standard guidelines (30) . ER, estrogen receptor; PR, progesterone receptor; HER2, c-erbB-2.
(pPMSKH1-RESTmt) changed 3 nucleotides (italics): 5Ј gtg taa ttt ata gtg tca c 3Ј. p␤-gal and pTK-Hyg were obtained from Clontech. TAC1 reporter vector, pGL3-PPT-I-1.2, which contains Intron 1 and upstream sequences, has been described (25) . REST expression vector, pCMV6-XL4-REST, and the empty vector were obtained from OriGene.
Stable knockdown of REST was done as previously described (4) . Briefly, cells were cotransfected with pPMSKH1-RESTwt or pPMSKH1-RESTmt and pHyg and then selected with 25 g/mL hygromycin. Ectopic REST expression in MDA-MB-231 was done with pCMV6-XL4-REST or vector alone and then selected with 0.5 g/mL neomycin. REST expressions were verified by Western blots and RT-PCR for protein and mRNA, respectively, as previously described (15) .
Reporter Gene Assay. Cells were cotransfected with p␤-gal and pGL3-PPT-I/1.2 with Effectene (Qiagen) (13) . Cell extracts were analyzed for total protein with an assay kit from Bio-Rad. Normalizations were computed with the ratio of luciferase to ␤-gal activity as previously described (25) .
Real-Time RT-PCR. Real-time PCR was performed with 200 ng cDNA and TAC1-or REST-specific primers as previously described (15) . The reactions used the Platinum SYBR Green qPCR SuperMix UDG Kit (Invitrogen). Amplifications were done on a 7300 Real Time PCR System (Applied Biosystems. The cycling profiles were 94°C for 15 s and 60°C for 45 s. The reactions were normalized by amplifying the same cDNA with ␤-actin primers.
Western Blots and Densitometries. Cell extracts were analyzed by Western blots on gradient SDS-PAGE (BioRad), as previously described (2) . Proteins were transferred onto polyvinyl membranes and then incubated with primary and secondary antibodies at dilutions of 1:1,000 and 1:2,000, respectively. Bands were detected by chemiluminescence. HeLa cell nuclear extract served as a positive control for REST detection. Band densities were determined with the UN-SCAN-IT gel software (Silk Scientific) and then normalized with bands for housekeeping genes.
Substance P ELISA. Media were quantitated for SP levels by competitive ELISA as previously described (29) . Briefly, 96-well plates were coated with a complex of streptavidin-biotinylated SP. Equal volumes (50 L) of the samples and optimum rabbit anti-SP were added to triplicate wells. Bound anti-SP was screened with alkaline phosphatase-conjugated goat antirabbit IgG and Sigma 104 phosphatase substrate.
Growth Curve. The method for growth curve analysis was performed as previously described (2). Briefly, BCCs (100/mL) were seeded in 60-mm tissue culture dishes and allowed to adhere overnight. The total number of viable cells was counted daily up to Day 5.
Migration Assay. BCC migration was assessed in a Boyden chamber with 8-m inserts as previously described (4) . Briefly, cells were labeled with CellTracker Green 5-chloromethylfluorescein diacetate according to the manufacturer's instructions (Invitrogen). Labeling efficiency, as determined by fluorescence microscopy, indicated Ͼ95% labeling efficiency. Labeled BCCs (10 4 ) were added to the inner chamber in sera-free culture media. After 2 h, migration was determined as described using Typhoon (Amersham Pharmacia, Molecular Dynamics), and then the mean fluorescence intensity was calculated with Image Quant software. The percentage of cell migration was calculated on a standard curve of total BCCs vs. fluorescence intensity.
Statistical Analyses. Statistical evaluations of data were performed with analysis of variance and the Tukey-Kramer multiple comparisons test. A P value of Ͻ0.05 was considered significant.
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